Augmented antitumor effects of combination therapy of cisplatin with   ethaselen as a novel thioredoxin reductase inhibitor on human A549 cell   in vivo

doi:10.1007/s10637-009-9235-7

CORC > 北京大学 > 生命科学学院

	Augmented antitumor effects of combination therapy of cisplatin with ethaselen as a novel thioredoxin reductase inhibitor on human A549 cell in vivo
	Tan, Qiang ; Li, Jing ; Yin, Han-wei ; Wang, Li-hui ; Tang, Wan-chen ; Zhao, Fang ; Liu, Xin-min ; Zeng, Hui-hui
刊名	investigational new drugs
	2010
关键词	Ethaselen Thioredoxin reductase inhibitor Cisplatin Non-small cell lung cancer Combination chemotherapy Synergistic effect LUNG-CANCER CELLS MAMMALIAN THIOREDOXIN POSSIBLE INVOLVEMENT CYCLE ARREST APOPTOSIS CARCINOMA DESIGN GROWTH LINES CIS-DIAMMINEDICHLOROPLATINUM(II)
DOI	10.1007/s10637-009-9235-7
英文摘要	Ethaselen (1, 2-[bis (1, 2-Benzisoselenazolone-3 (2H) -ketone)] ethane, BBSKE), as a novel organoselenium compound targeting thioredoxin reductase (TrxR), has been reported to inhibit tumor growth and TrxR activity in several human tumor cell lines. It has now entered Phase I clinical trails. Here we report the effects of ethaselen and cisplatin (cis-diamminedichloroplatinum II, DDP) combination therapy (ethaselen 36 mg/kg, i.g., o.d. x 10 d and cisplatin 1 mg/kg, i.p., single at day 0) on human A549-grafted nude mouse model (female, BALB/c nude mouse, n = 5, treatment after tumor volume reached 100 mm(3)). Compared to single drug administration (either ethaselen: 36 mg/kg, i.g., o.d. x 10 d or cisplatin: 1.0 mg/kg, i.p., single at day 0), the combination therapy showed significantly reduced tumor size (presumably due to a synergistic effect) and no obvious toxic damage (both in terms of body weight maintenance and liver/kidney damage). These results will be significant in the development of novel anti-tumoral therapeutic strategies directed to non-small cell lung cancer (NSCLC).; http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000276430200001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=8e1609b174ce4e31116a60747a720701 ; Oncology; Pharmacology & Pharmacy; SCI(E); PubMed; 24; ARTICLE; 3; 205-215; 28
语种	英语
内容类型	期刊论文
源URL	[http://ir.pku.edu.cn/handle/20.500.11897/156868]
专题	生命科学学院
推荐引用方式 GB/T 7714	Tan, Qiang,Li, Jing,Yin, Han-wei,et al. Augmented antitumor effects of combination therapy of cisplatin with ethaselen as a novel thioredoxin reductase inhibitor on human A549 cell in vivo[J]. investigational new drugs,2010.
APA	Tan, Qiang.,Li, Jing.,Yin, Han-wei.,Wang, Li-hui.,Tang, Wan-chen.,...&Zeng, Hui-hui.(2010).Augmented antitumor effects of combination therapy of cisplatin with ethaselen as a novel thioredoxin reductase inhibitor on human A549 cell in vivo.investigational new drugs.
MLA	Tan, Qiang,et al."Augmented antitumor effects of combination therapy of cisplatin with ethaselen as a novel thioredoxin reductase inhibitor on human A549 cell in vivo".investigational new drugs (2010).